CClinicalTrials.gg
Not yet recruitingNCT07250464Updated Nov 28, 2025

Motor Evoked Potential and Cortical Silent Period in Migraine

An interventional study of Transcranial Magnetic Stimulation (TMS) and Surface Electromyography (sEMG) in Migraine and Healty Controls, sponsored by Istanbul Gelisim University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Istanbul Gelisim University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary objective of this study is to assess the level of inhibitory control in the motor cortex of migraine patients using objective and non-invasive methods. To this end, Motor Evoked Potential (MEP) and Cortical Silence Period (CSP) parameters obtained using Transcranial Magnetic Stimulation (TMS) will be measured and comparisons will be made between migraine patients and healthy controls. Since CSP duration is used specifically in the evaluation of GABA-B-mediated inhibitory mechanisms, it has the potential to directly measure the effect of migraine on cortical inhibition.

Read the detailed description

Rationale and Background:

Migraine is a neurological disorder that significantly impairs individual quality of life and imposes substantial economic burdens on healthcare systems worldwide. Although its pathophysiology is not fully understood, recent research suggests that migraine is associated not only with vascular changes but also with alterations at neurological and cortical levels (Goadsby et al., 2017). Evidence increasingly indicates enhanced excitability and disrupted inhibitory mechanisms in central nervous system regions, including the motor cortex (Coppola et al., 2007).

Transcranial Magnetic Stimulation (TMS) is a non-invasive and reliable neurophysiological technique that stimulates the motor cortex and records muscle responses. Parameters obtained through TMS, such as Motor Evoked Potential (MEP) and Cortical Silent Period (CSP), are used to assess cortical excitability and inhibitory control, respectively (Chen et al., 1999). CSP is particularly useful for evaluating GABA-B-mediated inhibitory mechanisms. The hypothesis that migraine patients exhibit reduced cortical inhibition can be directly tested using CSP measurements.

Previous studies have reported shortened CSP durations and increased MEP amplitudes in migraine patients, suggesting cortical hyperexcitability (Brighina et al., 2002; Afra et al., 1998). However, these findings are inconsistent, and how they vary across migraine subtypes (with aura vs. without aura) remains unclear. Therefore, this study aims to characterize cortical physiological changes in migraine using objective and quantitative measures, filling gaps in the literature and contributing to clinical evaluations. Additionally, the relationship of these parameters with clinical features such as migraine type, duration, and attack frequency will be investigated to lay the groundwork for individualized neurophysiological profiling.

Primary and Secondary Objectives:

Primary Objective:

The primary objective of this study is to objectively evaluate inhibitory control in the motor cortex of migraine patients using non-invasive methods. Motor Evoked Potentials (MEP) and Cortical Silent Periods (CSP) obtained through TMS will be measured and compared between migraine patients and healthy controls. CSP duration, reflecting GABA-B-mediated inhibitory mechanisms, allows direct assessment of migraine's effect on cortical inhibition (Chen et al., 1999).

Secondary Objectives:

Motor Output Analysis: Electromyographic (EMG) signals will be analyzed using Peristimulus Time Histogram (PSTH) and Peristimulus Frequencygram (PSF) methods to assess the temporal pattern and frequency changes of motor unit responses following TMS. PSTH analyzes the timing of individual motor units after stimulation, while PSF provides a more precise view of post-stimulation frequency changes (Türker \& Powers, 2001). These analyses help reveal the spinal reflection of cortical stimulation and its effect on motor output.

Biomarker Potential: TMS-derived parameters such as CSP and MEP will be evaluated for their potential as biomarkers of migraine pathophysiology, contributing to the development of objective measures for future diagnosis and treatment.

Expected Benefits:

At the end of this study, it is expected to obtain objective data on motor cortical inhibitory capacity in migraine patients. TMS parameters, particularly CSP and MEP, can be used to understand the neurophysiological basis of migraine. The results may provide:

Improved understanding of cortical excitability and inhibition balance in migraine pathophysiology.

Foundational data for the development of objective diagnostic biomarkers for migraine.

Evidence of cortical dysfunction in migraine patients, supporting personalized treatment approaches.

A comprehensive understanding of motor output from cortical to spinal levels via electrophysiological analyses (PSTH/PSF).

All procedures are non-invasive and safe, providing a reproducible and ethical research approach.

Study Methods:

Participants:

The study will include right-handed individuals aged 18-45 years with a prior diagnosis of migraine according to the International Headache Society (IHS) criteria.

Data Collection:

The study will use non-invasive brain stimulation (TMS) along with surface electromyography (sEMG) and needle EMG. Measurements will be performed both at rest and during voluntary muscle contraction. TMS will be applied over the motor cortex, and muscle responses will be recorded simultaneously using sEMG electrodes. For detailed motor neuron analysis, single motor unit (SMU) recordings will also be obtained.

Needle EMG/SMU Recording:

SMU recordings will use sterile, Teflon-coated needles containing copper wires (approximately 70 μm diameter, 25G) inserted into the first dorsal interosseous (FDI) muscle. Needles will be partially retracted to maintain electrode stability, allowing single motor unit activity to be recorded even during movement.

TMS Application:

TMS will be performed using a Magstim 200\^2 Monophasic Stimulator (Magstim Ltd, UK) with a 70 mm figure-of-eight coil placed over the dominant hemisphere's primary motor cortex (M1) corresponding to the FDI muscle. Resting Motor Threshold (RMT) will be determined, followed by stimulation to elicit MEPs.

Surface EMG Recording:

sEMG signals will be obtained using Ag/AgCl electrodes placed over the FDI muscle. Signals will be amplified with a CED 1902 amplifier and digitized via CED 3601 Power 1401 DAC unit. MEP latencies and amplitudes, as well as CSP durations, will be calculated. Participants will maintain \~20% maximal voluntary contraction during measurements.

Data Analysis:

Data will be analyzed using IBM SPSS Statistics 26. Normality will be tested using Kolmogorov-Smirnov and Shapiro-Wilk tests. Parametric data will be analyzed using independent t-tests and ANOVA, while non-parametric data will be analyzed with Mann-Whitney U or Kruskal-Wallis tests. Correlations between clinical parameters (migraine duration, frequency, severity) and neurophysiological measures (MEP, CSP) will be assessed using Pearson or Spearman correlation coefficients, with significance set at p \< 0.05.

02

Conditions studied

  • Migraine
  • Healty Controls

Browse trials for

Keywords

  • cortical silent period
  • migraine
  • single motor unit
  • transcranial magnetic stimulation
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 18-45 years.
  • Right-handed individuals.
  • Migraine patients: diagnosed according to International Headache Society (IHS) criteria.
  • Healthy controls: no history of migraine or other neurological disorders.
  • Able and willing to provide informed consent.

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy or other seizure disorders.
  • Presence of metal implants, pacemakers, or other contraindications to TMS.
  • Pregnancy or breastfeeding.
  • History of significant neurological or psychiatric disorders.
  • Use of medications that significantly alter cortical excitability (e.g., antiepileptics, benzodiazepines) in the last 2 weeks.
  • Any musculoskeletal condition preventing safe participation in EMG/TMS procedures.
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Migraine Patients

    Adult participants aged 18-45 with a prior diagnosis of migraine according to IHS criteria. Transcranial Magnetic Stimulation (TMS) Surface Electromyography (sEMG) Needle EMG / Single Motor Unit (SMU) Recording

    Other: Transcranial Magnetic Stimulation (TMS) · Device: Surface Electromyography (sEMG) · Other: Needle EMG / Single Motor Unit (SMU) Recording

  • Sham comparator
    Healthy Controls

    Age- and sex-matched adults without a history of migraine or neurological disorders. They undergo the same sEMG and needle EMG/SMU procedures as the migraine group, but the TMS is sham. Surface Electromyography (sEMG) Needle EMG / Single Motor Unit (SMU) Recording Transcranial Magnetic Stimulation (TMS) SHAM

    Device: Surface Electromyography (sEMG) · Other: Needle EMG / Single Motor Unit (SMU) Recording

Interventions

  • OtherTranscranial Magnetic Stimulation (TMS)

    Non-invasive brain stimulation applied to the primary motor cortex to elicit motor evoked potentials (MEP) and cortical silent periods (CSP). 70 mm figure-of-eight coil used with Magstim 200² Monophasic Stimulator.

  • DeviceSurface Electromyography (sEMG)

    Bipolar Ag/AgCl electrodes placed over the first dorsal interosseous (FDI) muscle to record muscle responses to TMS.

  • OtherNeedle EMG / Single Motor Unit (SMU) Recording

    Sterile Teflon-coated needle electrodes inserted into the FDI muscle to record activity of individual motor units during TMS and voluntary contractions.

05

What researchers measure

Primary outcomes

  1. Cortical Silent Period (CSP) Duration

    CSP duration will be recorded from the first dorsal interosseous (FDI) muscle using surface EMG during TMS. CSP reflects GABA-B-mediated cortical inhibitory mechanisms, allowing direct assessment of cortical inhibition in migraine patients compared to healthy controls.

    Time frame: Single session measurement during TMS

Secondary outcomes

  1. Motor Evoked Potential (MEP) Amplitude

    MEP amplitudes will be recorded from FDI muscle using surface EMG. Changes in MEP amplitude reflect cortical excitability and motor output.

    Time frame: Single session measurement during TMS

Other outcomes

  1. Correlation Between Neurophysiological Parameters and Disease Duration

    The relationship between TMS parameters (CSP duration, MEP amplitude) and the duration of the migraine disorder will be assessed using correlation analysis (Pearson or Spearman). Disease duration is determined based on the patient's medical history interview.

    Time frame: Single session measurement during TMS

  2. Single Motor Unit (SMU) Firing Rate

    The discharge rate (firing frequency) of single motor units recorded from the first dorsal interosseous (FDI) muscle using needle EMG during voluntary contraction.

    Time frame: Single session measurement during TMS

06

Study locations

1 site
  • Istanbul Gelisim University, Faculty of Dentistry, Translational Dentistry Research Laboratory
    Istanbul, Istanbul 34310, Turkey (Türkiye)
    • Murat Kara, MSc · Contact · murkara@gelisim.edu.tr · +905314708141
    • Kemal Sıtkı Türker, Prof. Dr. · Contact · ksturker@gelisim.edu.tr · +905325987791
    • Kemal Sıtkı Türker, Prof. Dr. · Principal investigator
    • Murat Kara, MSc · Sub investigator
    • Muhammed Yurtseven, MSc · Sub investigator
    • Nilgün Yıldız, MSc · Sub investigator
07

References and documents

Publications

  • Haavik H, Niazi IK, Jochumsen M, Ugincius P, Sebik O, Yilmaz G, Navid MS, Ozyurt MG, Turker KS. Chiropractic spinal manipulation alters TMS induced I-wave excitability and shortens the cortical silent period. J Electromyogr Kinesiol. 2018 Oct;42:24-35. doi: 10.1016/j.jelekin.2018.06.010. Epub 2018 Jun 19. PubMed 29936314 ↗
  • Ozyurt MG, Haavik H, Nedergaard RW, Topkara B, Senocak BS, Goztepe MB, Niazi IK, Turker KS. Transcranial magnetic stimulation induced early silent period and rebound activity re-examined. PLoS One. 2019 Dec 4;14(12):e0225535. doi: 10.1371/journal.pone.0225535. eCollection 2019. PubMed 31800618 ↗
  • Todd G, Rogasch NC, Turker KS. Transcranial magnetic stimulation and peristimulus frequencygram. Clin Neurophysiol. 2012 May;123(5):1002-9. doi: 10.1016/j.clinph.2011.09.019. Epub 2011 Oct 22. PubMed 22019353 ↗
  • Haavik, H., Özyurt, M. G., Niazi, I. K., Nedergaard, R. W., Topkara, B., Yilmaz, G., & Türker, K. S. (2018). Re-investigation on the nature and sign of transcranial magnetic stimulation-induced cortical silent period. In 11th Biennial Meeting of the International Motoneuron Society, IBS, 11-14 June 2018, Boulder, CO, USA (pp. 28-29). Article 46 https://motoneuron2018.org/wp-content/uploads/2018/05/IMS-Poster-Abstracts-2018.pdf
  • Kahya MC, Yavuz SU, Turker KS. Cutaneous silent period in human FDI motor units. Exp Brain Res. 2010 Sep;205(4):455-63. doi: 10.1007/s00221-010-2380-6. Epub 2010 Aug 8. PubMed 20694723 ↗

Study documents

  • Study protocol · Oct 3, 2025
  • Informed consent form · Oct 3, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — Individual participant data (EMG and TMS measurements) will not be shared outside of the published study results to protect participant confidentiality and privacy.

08

Registry details

Key details

Study ID
NCT07250464
Lead sponsor
Istanbul Gelisim University
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Jan 1, 2026 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Nov 28, 2025

Study contacts

Murat Kara, MSc
Contact
murkara@gelisim.edu.tr
+905314708141
Kemal Sıtkı Türker, Prof. Dr.
Contact
ksturker@gelisim.edu.tr
+905325987791
Kemal Sıtkı Türker, Prof. Dr.
principal investigator · Istanbul Gelisim University, Faculty of Dentistry, Translational Dentistry Research Laboratory

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion